FR3084584B1 - SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS - Google Patents

SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS Download PDF

Info

Publication number
FR3084584B1
FR3084584B1 FR1857267A FR1857267A FR3084584B1 FR 3084584 B1 FR3084584 B1 FR 3084584B1 FR 1857267 A FR1857267 A FR 1857267A FR 1857267 A FR1857267 A FR 1857267A FR 3084584 B1 FR3084584 B1 FR 3084584B1
Authority
FR
France
Prior art keywords
injection
amphiphilic compound
solution
human glucagon
hydrophobic radicals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1857267A
Other languages
French (fr)
Other versions
FR3084584A1 (en
Inventor
Emmanuel Dauty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1857267A priority Critical patent/FR3084584B1/en
Priority to PCT/EP2019/070953 priority patent/WO2020025825A1/en
Publication of FR3084584A1 publication Critical patent/FR3084584A1/en
Application granted granted Critical
Publication of FR3084584B1 publication Critical patent/FR3084584B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

[0001] L'invention concerne une composition stable physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : - du glucagon humain, et - un composé amphiphile comprenant un squelette hydrophile HB, substitué par au moins un radical hydrophobe -Hy de formule I.The invention relates to a physically stable composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least: - human glucagon, and - an amphiphilic compound comprising a hydrophilic backbone HB, substituted by at least one hydrophobic radical -Hy of formula I.

FR1857267A 2018-08-03 2018-08-03 SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS Active FR3084584B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1857267A FR3084584B1 (en) 2018-08-03 2018-08-03 SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
PCT/EP2019/070953 WO2020025825A1 (en) 2018-08-03 2019-08-03 Injectable solution having ph 7 and comprising human glucagon, at least one ionic species, and an amphiphilic compound bearing hydrophobic radicals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1857267 2018-08-03
FR1857267A FR3084584B1 (en) 2018-08-03 2018-08-03 SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS

Publications (2)

Publication Number Publication Date
FR3084584A1 FR3084584A1 (en) 2020-02-07
FR3084584B1 true FR3084584B1 (en) 2020-11-06

Family

ID=65201005

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1857267A Active FR3084584B1 (en) 2018-08-03 2018-08-03 SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS

Country Status (2)

Country Link
FR (1) FR3084584B1 (en)
WO (1) WO2020025825A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4091625A1 (en) 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JP2019517560A (en) * 2016-06-07 2019-06-24 アドシア Composition in the form of an injectable solution comprising human glucagon and copolyamino acids
WO2017211926A1 (en) * 2016-06-08 2017-12-14 Prysmian S.P.A. Traceable power cable and method

Also Published As

Publication number Publication date
FR3084584A1 (en) 2020-02-07
WO2020025825A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
FR3084584B1 (en) SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
JOP20200160A1 (en) Aqueous suspensions of TMC278
EA202092899A1 (en) HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
EP4252848A3 (en) Oxysterols and methods of use thereof
MD4584B1 (en) Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
EA201890888A1 (en) NEW SPIRO [3H-INDOL-3,2'-PYRROLIDIN] -2 (1H) -ONE COMPOUNDS AND DERIVATIVES AS INHIBITORS MDM2-P53
EA201892007A1 (en) 3-DESOXY DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS ON ITS BASIS
EA200601648A1 (en) GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS
CY1105362T1 (en) SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
CR20220675A (en) 1'-cyano nucleoside analogs and uses thereof
CY1113824T1 (en) INTENSIVE COMPOSITIONS
MY150091A (en) Prevention of hiv-infection
CR20230100A (en) Phospholipid compounds and uses thereof
ATE454905T1 (en) STABLE INJECTABLE DICLOFENAC PREPARATIONS
MX2020008359A (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclo.
NO20060896L (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
EA202092069A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR DYSTROPHY
ATE548043T1 (en) POLYMORPHS OF 3-O-(3',3'-DIMETHYLSUCCINYL)BETULINIC ACID-DI-N-METHYL-D-GLUCAMINE
CL2007001747A1 (en) Compounds derived from aryl and heteroaryl-ethyl-acylguanidine; preparation procedure; pharmaceutical composition; and use for the treatment and prevention of hypertension, heart failure and kidney conditions among others.
WO2023049829A3 (en) Cyclic peroxides as prodrugs for selective delivery of agents
FR3084586B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
CY1124270T1 (en) OPHTHALMIC COMPOSITIONS COMPRISING VILASTIN, A B-CYCLODEXTRIN AND AT LEAST ONE THICKENING AGENT
FR3084585B1 (en) SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200207

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6